DPP4 and COVID-19: The beneficial effect of DPP4 inhibitors on COVID-19 outcomes was raised; however, only retrospective analyses are available and not all of these reports consistently demonstrated a beneficial effect [9,10,39,40,41,42,43,44]; the results from prospective trials are lacking.